SUPN stock forecast
Our latest prediction for Supernus Pharmaceuticals, Inc.'s stock price was made on the Aug. 23, 2019 when the stock price was at 26.13$.
In the short term (2weeks), SUPN's stock price should outperform the market by 2.39%. During that period the price should oscillate between -4.60% and +7.27%.
In the medium term (3months), SUPN's stock price should outperform the market by 2.50%. During that period the price should oscillate between -12.28% and +18.08%.Get email alerts
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
At the moment the company generates 409M USD in revenues.
On its last earning announcement, the company reported a profit of 1.94$ per share.
The book value per share is 7.48$
Three months stock forecastAug. 23, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|